Free Trial
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel
NASDAQ:ACON

Aclarion Q1 2025 Earnings Report

Aclarion logo
$3.57 +0.04 (+1.13%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$3.42 -0.16 (-4.34%)
As of 06/5/2026 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aclarion EPS Results

Actual EPS
-$9.32
Consensus EPS
-$1,447.20
Beat/Miss
Beat by +$1,437.88
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.02 million
Beat/Miss
Missed by -$1.00 thousand
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q1 2025
Date
5/15/2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Aclarion's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Aclarion's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Aclarion Earnings Headlines

Wall Street Zen Downgrades Aclarion (NASDAQ:ACON) to Sell
June 6 at 1:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30821814
Aclarion Stockholders Approve Directors and Equity Plan Amendment
June 4 at 7:10 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/aclarion-stockholders-approve-directors-and-equity-plan-amendment?utm_source=marketbeat.com&utm_medium=referral
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.tc pixel
June 6 at 1:00 AM  |  Behind the Markets (Ad)
Aclarion Expands Nociscan Availability in Greater Los Angeles Through Partnership with Institute of Neuro Innovation
June 3 at 6:31 AM  |  quiverquant.comQ
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
June 3 at 6:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305854/0/en/aclarion-adds-institute-of-neuro-innovation-to-support-nociscan-growth-and-real-world-evidence-generation.html
Aclarion's Nociscan Technology Linked to Immune Signatures in Back Pain Study, Expanding Clinical Applications
June 1, 2026  |  quiverquant.comQ
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile
Earnings Tools